1-3 of 3
Matthias Klinger, PhD
Close
Sort by
Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD
Journal: Blood
Blood (2016) 128 (22): 1589.
https://doi.org/10.1182/blood.V128.22.1589.1589
Published: 2016
Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Max S Topp, Gerhard Zugmaier, MD, Nicola Goekbuget, MD, Svenja Neumann, MD, Heinz-August Horst, MD, Thorsten Raff, MD, Monika Brueggemann, MD, Michael Kneba, MD, Andreas Viardot, MD, Mathias Schmid, MD, Markus Schaich, MD, Matthias Stelljes, MD, Mariele Goebeler, MD, Heike Pfeiffer, MD, Oliver Ottmann, MD, Thomas Burmeister, MD, Evelyn Degenhard, Margit Schmidt, PhD, Jürgen Scheele, MD, PhD, Hermann Einsele, MD, Peter Kufer, MD, Matthias Klinger, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 174.
https://doi.org/10.1182/blood.V116.21.174.174
Published: 2010
Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 2880.
https://doi.org/10.1182/blood.V116.21.2880.2880
Published: 2010